82152 Planegg, de
+49 (89) 895574-0
BIOMAX INFORMATICS collaborates with Pierre Fabre to provide a research environment to support therapeutic antibody development
Biomax used their BioXM™ Knowledge Management Environment to configure a centralized antibody sequence and knowledge base that supports Pierre Fabre's antibody discovery process. The knowledge base comprises sophisticated sequence analysis and storage, a platform to share in-house data and algorithms, public data, and both public and third-party algorithms. Pierre Fabre researchers have quickly adopted the platform to collect and generate further knowledge.
"We have improved our database quality by a centralized bioinformatics system tailored to our needs in analyzing and validating our antibody discovery data," said Dr. M. Tesar, Head of the Molecular and Cellular Department at Pierre Fabre Immunology Center. "We were impressed how quickly Biomax took our experts' concepts and turned them into a software solution that efficiently supports our daily work. The improvement to our antibody R&D process has been invaluable."
"This project represents exactly what Biomax strives to do: give researchers the tools that help them leverage their big concepts, capture knowledge and add value to their research," said Dr. Philipp Krubasik, Director of Key Accounts at Biomax. "The BioXM platform was developed to be a flexible knowledge management system that can be configured to any area within life sciences to provide sustainable research support. We're pleased that Pierre Fabre sees the potential to expand this project to support multiple disciplines along their complete antibody development pipeline."
About the BioXM Knowledge Management platform
The BioXM Knowledge Management Environment is a project-centered, distributed software platform that provides a central inventory of information and knowledge. Users create, manage and visualize scientific models as an extendible network of interrelated concepts. The BioXM system facilitates communication and collaboration within research environments, allowing researchers to focus on science.
About Pierre Fabre
Pierre Fabre is the third largest French pharmaceutical group. In 2013, its sales reached €2.008 billion, with international revenues accounting for 56%. Founded and still based in southwest France, Pierre Fabre currently has branches in 44 countries and distribution agreements in over 130 countries.
Covering all aspects of healthcare, from prescription drugs and OTC products to dermo-cosmetics, Pierre Fabre Laboratories employ over 10,000 people worldwide. In 2013, Pierre Fabre allocated more than 17% of its drug revenues to R&D, focusing on three main areas: oncology, dermatology and neuropsychiatry.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.